Patient population for bioequivalence study [Regulatives / Guidelines]

posted by DavidManteigas – Portugal, 2017-10-06 12:34 (2686 d 20:32 ago) – Posting: # 17866
Views: 3,720

It is hard to provide a valuable opinion without knowing much details, namely whether you're talking about a biosimilar or generic. :-D

Generally, the product-specific guideline states in which condition should be bioequivalence study be performed. For instance, in USA diclofenac is approved for 3 indications but for BE only a study in subjects with osteoarthritis of the knee is required (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm244644.pdf). If no product-specific guideline exists, I would recommend you to ask for scientific advice on which patient population should be selected for the BE study with clinical endpoint. If I were the Sponsor, I would pick the condition on which the primary endpoint presents less variability in the outcome.

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,661 registered users;
27 visitors (0 registered, 27 guests [including 4 identified bots]).
Forum time: 08:07 CET (Europe/Vienna)

Everything is trivial, if you know the answer.    Thomas Jaki

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5